

# Ioannis Ntanasis-Stathopoulos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5424641/publications.pdf>

Version: 2024-02-01

178  
papers

5,897  
citations

117625

34  
h-index

95266

68  
g-index

180  
all docs

180  
docs citations

180  
times ranked

10066  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hematological findings and complications of COVID-19. American Journal of Hematology, 2020, 95, 834-847.	4.1	1,354
2	Organ-specific manifestations of COVID-19 infection. Clinical and Experimental Medicine, 2020, 20, 493-506.	3.6	351
3	Emerging treatment strategies for COVID-19 infection. Clinical and Experimental Medicine, 2021, 21, 167-179.	3.6	232
4	Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer Journal, 2018, 8, 7.	6.2	219
5	Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence. Surgical Oncology, 2018, 27, 280-288.	1.6	132
6	Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. Blood, 2021, 137, 3674-3676.	1.4	130
7	Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review. Journal of Infection, 2021, 83, 1-16.	3.3	127
8	Liver transplantation in patients with liver metastases from neuroendocrine tumors: A systematic review. Surgery, 2017, 162, 525-536.	1.9	126
9	Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia, 2020, 34, 2000-2011.	7.2	109
10	The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer Journal, 2021, 11, 138.	6.2	103
11	Impact of Surgical Margin Width on Recurrence and Overall Survival Following R0 Hepatic Resection of Colorectal Metastases. Annals of Surgery, 2018, 267, 1047-1055.	4.2	102
12	Anatomic versus non-anatomic resection for hepatocellular carcinoma: A systematic review and meta-analysis. European Journal of Surgical Oncology, 2018, 44, 927-938.	1.0	97
13	Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncology, The, 2021, 22, e119-e130.	10.7	92
14	Myeloma bone disease: from biology findings to treatment approaches. Blood, 2019, 133, 1534-1539.	1.4	88
15	Management and Outcomes in Metaplastic Breast Cancer. Clinical Breast Cancer, 2016, 16, 437-443.	2.4	66
16	Obesity and Risk for Brain/CNS Tumors, Gliomas and Meningiomas: A Meta-Analysis. PLoS ONE, 2015, 10, e0136974.	2.5	64
17	Neuroendocrine Neoplasms of the Appendix: A Review of the Literature. Anticancer Research, 2018, 38, 601-611.	1.1	64
18	Management, outcomes, and prognostic factors of ruptured hepatocellular carcinoma: A systematic review. Journal of Surgical Oncology, 2018, 117, 341-353.	1.7	61

#	ARTICLE	IF	CITATIONS
19	CCL3 Signaling in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1231, 13-21.	1.6	60
20	Association between problematic internet use, socio-demographic variables and obesity among European adolescents. <i>European Journal of Public Health</i> , 2016, 26, 617-622.	0.3	58
21	Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective. <i>Surgical Oncology</i> , 2018, 27, 611-618.	1.6	57
22	The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. <i>Blood</i> , 2018, 131, 464-467.	1.4	54
23	SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors. <i>European Journal of Internal Medicine</i> , 2021, 89, 87-96.	2.2	53
24	Prevention and treatment of childhood and adolescent obesity: a systematic review of meta-analyses. <i>World Journal of Pediatrics</i> , 2019, 15, 350-381.	1.8	49
25	Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study. <i>Cancers</i> , 2021, 13, 4480.	3.7	44
26	Multiple myeloma: Role of autologous transplantation. <i>Cancer Treatment Reviews</i> , 2020, 82, 101929.	7.7	42
27	Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies. <i>Leukemia</i> , 2018, 32, 2617-2625.	7.2	40
28	Physical Activity and Gastric Cancer Risk. <i>Clinical Journal of Sport Medicine</i> , 2016, 26, 445-464.	1.8	39
29	Is Resection of Primary Midgut Neuroendocrine Tumors in Patients with Unresectable Metastatic Liver Disease Justified? A Systematic Review and Meta-Analysis. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 1044-1054.	1.7	39
30	Anti-SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study. <i>Microorganisms</i> , 2020, 8, 1885.	3.6	39
31	The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4462.	4.1	39
32	Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study. <i>Blood Advances</i> , 2021, 5, 4398-4405.	5.2	39
33	Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. <i>Cells</i> , 2021, 10, 1942.	4.1	38
34	Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. <i>Blood Advances</i> , 2019, 3, 3002-3009.	5.2	37
35	Alcohol consumption and risk of hematological malignancies: A meta-analysis of prospective studies. <i>International Journal of Cancer</i> , 2018, 143, 486-495.	5.1	36
36	Anthropometric characteristics, physical activity and risk of hematological malignancies: A systematic review and meta-analysis of cohort studies. <i>International Journal of Cancer</i> , 2019, 145, 347-359.	5.1	36

#	ARTICLE	IF	CITATIONS
37	Late-onset hematological complications post COVID-19: An emerging medical problem for the hematologist. <i>American Journal of Hematology</i> , 2022, 97, 119-128.	4.1	36
38	Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches. <i>Frontiers in Oncology</i> , 2020, 10, 860.	2.8	35
39	Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1049-1061.	1.8	31
40	SARS-CoV-2 Vaccines in Patients With Multiple Myeloma. <i>HemaSphere</i> , 2021, 5, e547.	2.7	31
41	Cytokines as biomarkers of inflammatory response after open versus endovascular repair of abdominal aortic aneurysms: a systematic review. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 1164-1175.	6.1	30
42	Disappearing liver metastases: A systematic review of the current evidence. <i>Surgical Oncology</i> , 2019, 29, 7-13.	1.6	30
43	Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine. <i>Clinical and Experimental Medicine</i> , 2022, 22, 319-323.	3.6	30
44	Squamous cell carcinoma of the pancreas: A systematic review and pooled survival analysis. <i>European Journal of Cancer</i> , 2017, 79, 193-204.	2.8	29
45	Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 42.	6.2	29
46	Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy. <i>Blood</i> , 2022, 139, 1409-1412.	1.4	28
47	COVID-19: time to flatten the infodemic curve. <i>Clinical and Experimental Medicine</i> , 2021, 21, 161-165.	3.6	27
48	Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection. <i>Viruses</i> , 2021, 13, 26.	3.3	26
49	High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events. <i>Vaccines</i> , 2021, 9, 712.	4.4	25
50	BCMA in Multiple Myeloma—A Promising Key to Therapy. <i>Journal of Clinical Medicine</i> , 2021, 10, 4088.	2.4	25
51	Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals. <i>Life</i> , 2021, 11, 1077.	2.4	25
52	Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 793953.	4.8	25
53	Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 234-241.	3.0	24
54	Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma. <i>Cancers</i> , 2020, 12, 3245.	3.7	24

#	ARTICLE	IF	CITATIONS
55	Consumption of fruits, vegetables, and risk of hematological malignancies: a systematic review and meta-analysis of prospective studies. <i>Leukemia and Lymphoma</i> , 2018, 59, 434-447.	1.3	23
56	Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 445-452.	0.4	23
57	Update on Surgical Management of Small Bowel Neuroendocrine Tumors. <i>Anticancer Research</i> , 2018, 38, 1267-1278.	1.1	23
58	Current Approaches in the Management of Hepatic Adenomas. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 199-209.	1.7	21
59	Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates. <i>American Journal of Hematology</i> , 2019, 94, 400-407.	4.1	21
60	Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222. <i>Biomedicines</i> , 2022, 10, 338.	3.2	21
61	Program death-1 immune checkpoint and tumor microenvironment in malignant liver tumors. <i>Surgical Oncology</i> , 2017, 26, 423-430.	1.6	20
62	Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy. <i>HemaSphere</i> , 2019, 3, e300.	2.7	20
63	The association between pulse wave velocity and peripheral neuropathy in patients with type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1624-1629.	2.3	19
64	The role of BioGlue in thoracic surgery: a systematic review. <i>Journal of Thoracic Disease</i> , 2017, 9, 568-576.	1.4	19
65	Anti-BCMA antibodies in the future management of multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 319-326.	2.4	19
66	Updates and Critical Insights on Glissonian Approach in Liver Surgery. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 154-163.	1.7	18
67	Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 3-11.	3.0	18
68	Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine. <i>British Journal of Haematology</i> , 2022, 196, 356-359.	2.5	18
69	Comparison of MRI Features of Fat Fraction and ADC for Early Treatment Response Assessment in Participants with Multiple Myeloma. <i>Radiology</i> , 2022, 304, 137-144.	7.3	18
70	The Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review. <i>Cancer Investigation</i> , 2016, 34, 313-339.	1.3	17
71	Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone. <i>Blood Advances</i> , 2019, 3, 4095-4103.	5.2	17
72	Multiple Myeloma Bone Disease: Implication of MicroRNAs in Its Molecular Background. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2375.	4.1	17

#	ARTICLE	IF	CITATIONS
73	Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?. American Journal of Hematology, 2021, 96, E321-E324.	4.1	17
74	Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals. HemaSphere, 2022, 6, e677.	2.7	17
75	Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma. Blood Cancer Journal, 2020, 10, 25.	6.2	16
76	Clinical Application of a New SARS-CoV-2 Antigen Detection Kit (Colloidal Gold) in the Detection of COVID-19. Diagnostics, 2021, 11, 995.	2.6	16
77	Metabolic Disorders in Multiple Myeloma. International Journal of Molecular Sciences, 2021, 22, 11430.	4.1	16
78	The Role of Endoscopic Ultrasound in the Diagnosis and Management of Primary Gastric Lymphoma. Gastroenterology Research and Practice, 2017, 2017, 1-6.	1.5	15
79	Meat, fish, dairy products and risk of hematological malignancies in adults – a systematic review and meta-analysis of prospective studies. Leukemia and Lymphoma, 2019, 60, 1978-1990.	1.3	15
80	Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance. British Journal of Haematology, 2021, 193, 113-118.	2.5	15
81	Insulin resistance and cardiometabolic risk factors in obese children and adolescents: a hierarchical approach. Journal of Pediatric Endocrinology and Metabolism, 2015, 28, 589-96.	0.9	14
82	Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial. Blood Advances, 2018, 2, 2837-2847.	5.2	14
83	Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome. HemaSphere, 2020, 4, e381.	2.7	14
84	Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection. Microorganisms, 2021, 9, 546.	3.6	14
85	Evaluating ibrutinib in the treatment of symptomatic Waldenström's macroglobulinemia. Journal of Blood Medicine, 2019, Volume 10, 291-300.	1.7	13
86	Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2018. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e324-e336.	0.4	13
87	The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma. Blood Cancer Journal, 2020, 10, 93.	6.2	13
88	Controversies in the use of new bone-modifying therapies in multiple myeloma. British Journal of Haematology, 2021, 193, 1034-1043.	2.5	13
89	Cholangiocarcinoma: investigations into pathway-targeted therapies. Expert Review of Anticancer Therapy, 2020, 20, 765-773.	2.4	13
90	A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma. International Journal of Molecular Sciences, 2021, 22, 13144.	4.1	13

#	ARTICLE	IF	CITATIONS
91	Micronutrient Intake and Risk of Hematological Malignancies in Adults: A Systematic Review and Meta-analysis of Cohort Studies. <i>Nutrition and Cancer</i> , 2018, 70, 821-839.	2.0	12
92	Monoclonal antibodies against RANKL and sclerostin for myeloma-related bone disease: can they change the standard of care?. <i>Expert Review of Hematology</i> , 2019, 12, 651-663.	2.2	12
93	<p></p>Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 6405-6416.	2.0	12
94	Cell-free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlations. <i>American Journal of Hematology</i> , 2020, 95, E148-E150.	4.1	12
95	A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 3877.	3.7	12
96	Distinct neutralization profile of spike variants by antibodies induced upon SARS-CoV-2 infection or vaccination. <i>American Journal of Hematology</i> , 2022, 97, E3.	4.1	12
97	Updates on thrombotic events associated with multiple myeloma. <i>Expert Review of Hematology</i> , 2019, 12, 355-365.	2.2	11
98	Clinical Updates Regarding Multiple Myeloma From the 2019 American Society of Hematology Annual Meeting. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 499-508.	0.4	11
99	Current and novel BTK inhibitors in Waldenström's macroglobulinemia. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072198958.	2.5	11
100	Real-World Treatment of Patients With Relapsed/Refractory Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 379-385.	0.4	11
101	Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma. <i>Cancer Journal (Sudbury, Mass )</i> , 2019, 25, 2-10.	2.0	10
102	Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma. <i>International Journal of Cancer</i> , 2019, 145, 559-568.	5.1	10
103	Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 57-62.	0.4	10
104	Determination of MYD88L265P mutation fraction in IgM monoclonal gammopathies. <i>Blood Advances</i> , 2022, 6, 189-199.	5.2	10
105	Third dose of the BNT162b2 vaccine results in very high levels of neutralizing antibodies against SARS-CoV-2: Results of a prospective study in 150 health professionals in Greece. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	10
106	Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implications. <i>American Journal of Hematology</i> , 2022, 97, 1142-1149.	4.1	10
107	Adipose-derived stem cells for breast reconstruction after breast surgery – preliminary results. <i>Case Reports in Plastic Surgery &amp; Hand Surgery</i> , 2017, 4, 35-41.	0.3	9
108	Clear cell neuroendocrine tumor of the lung: Diagnostic features of a rare pulmonary tumor. <i>Respiratory Medicine Case Reports</i> , 2018, 23, 52-54.	0.4	9

#	ARTICLE	IF	CITATIONS
109	Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome. <i>Annals of Hematology</i> , 2019, 98, 1427-1434.	1.8	9
110	Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 619-628.	1.3	9
111	Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period. <i>Annals of Hematology</i> , 2020, 99, 1257-1264.	1.8	9
112	Monitoring Plasma Cell Dyscrasias With Cell-free DNA Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e905-e909.	0.4	9
113	Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study. <i>Cancers</i> , 2021, 13, 1257.	3.7	9
114	How I treat elderly patients with plasma cell dyscrasias. <i>Aging</i> , 2018, 10, 4248-4268.	3.1	9
115	Esophageal remnant cancer 35 years after acidic caustic injury: A case report. <i>International Journal of Surgery Case Reports</i> , 2016, 25, 215-217.	0.6	8
116	Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 921-928.	2.4	8
117	Treatment of Bing-Neel syndrome with first line sequential chemoimmunotherapy. <i>Medicine (United Tj ETQq1 1,0,784314 rgBT /O</i>	1.0	8
118	Whole-Body Low-Dose CT in Multiple Myeloma: Diagnostic Value of Appendicular Medullary Patterns of Attenuation. <i>American Journal of Roentgenology</i> , 2021, 216, 742-751.	2.2	8
119	The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma. <i>Vaccines</i> , 2021, 9, 422.	4.4	8
120	Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 Patients. <i>Cancers</i> , 2021, 13, 4047.	3.7	8
121	Liver Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1296, 227-241.	1.6	8
122	tRNA Derivatives in Multiple Myeloma: Investigation of the Potential Value of a tRNA-Derived Molecular Signature. <i>Biomedicines</i> , 2021, 9, 1811.	3.2	8
123	Multiple myeloma: Current and future management in the aging population. <i>Maturitas</i> , 2020, 138, 8-13.	2.4	7
124	Antibody therapies for multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 295-303.	3.1	7
125	Insights into Novel Prognostic and Possible Predictive Biomarkers of Lung Neuroendocrine Tumors. <i>Cancer Genomics and Proteomics</i> , 2018, 15, 153-163.	2.0	7
126	Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis. <i>Biomedicines</i> , 2022, 10, 204.	3.2	7

#	ARTICLE	IF	CITATIONS
127	Rare manifestations of extramedullary myeloma: testicular plasmacytomas. <i>Leukemia and Lymphoma</i> , 2018, 59, 2002-2004.	1.3	6
128	Denosumab effects on serum levels of the bone morphogenetic proteins antagonist noggin in patients with transfusion-dependent thalassemia and osteoporosis. <i>Hematology</i> , 2019, 24, 318-324.	1.5	6
129	How I treat rituximab refractory patients with WM. <i>Oncotarget</i> , 2018, 9, 36824-36825.	1.8	6
130	Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study. <i>Cancers</i> , 2021, 13, 5057.	3.7	6
131	Immune response and adverse events after vaccination against SARS-CoV-2 in adult patients with transfusion-dependent thalassaemia. <i>British Journal of Haematology</i> , 2022, 197, 576-579.	2.5	6
132	Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study REBUILD. <i>Cancers</i> , 2022, 14, 2768.	3.7	6
133	Third Dose of the BNT162b2 Vaccine Results in Sustained High Levels of Neutralizing Antibodies Against SARS-CoV-2 at 6 Months Following Vaccination in Healthy Individuals. <i>HemaSphere</i> , 2022, 6, e747.	2.7	6
134	Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 431-437.	0.4	5
135	Impact of Daratumumab-Containing Induction on Stem Cell Mobilization and Collection, Engraftment and Hospitalization Parameters Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 3886-3886.	1.4	5
136	Challenging differential diagnosis of an extra-adrenal paraganglioma; the role of fine needle aspiration cytology. <i>Diagnostic Cytopathology</i> , 2017, 45, 565-568.	1.0	4
137	Intraductal papilloma of the breast in an 11-year-old male patient: a case report. <i>Pediatric Surgery International</i> , 2017, 33, 727-730.	1.4	4
138	Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or Tj ETQq0 0 0 rgBT /Overlock 10 Tf 2018, 59, 983-987.	1.3	4
139	The current role of BTK inhibitors in the treatment of Waldenström's Macroglobulinemia. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 663-674.	2.4	4
140	Consolidation with Carfilzomib, Lenalidomide and Dexamethasone (KRd) Following ASCT Results in High Rates of Minimal Residual Disease Negativity and Improves Bone Metabolism, in the Absence of Bisphosphonates, Among Newly Diagnosed Patients with Multiple Myeloma. <i>Blood</i> , 2019, 134, 3118-3118.	1.4	4
141	Nonselective proteasome inhibitors in multiple myeloma and future perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 335-347.	1.8	4
142	A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2021, 138, 2736-2736.	1.4	4
143	The Addition of IMiDs for Patients with Daratumumab-Refractory Multiple Myeloma Can Overcome Refractoriness to Both Agents. <i>Blood</i> , 2020, 136, 21-21.	1.4	4
144	Persisting Endothelial Cell Activation and Hypercoagulability after COVID-19 Recovery: The Prospective Observational ROADMAP-Post COVID-19 Study. <i>Hemato</i> , 2022, 3, 111-121.	0.6	4

#	ARTICLE	IF	CITATIONS
145	Diabetes mellitus and multiple myeloma; common features of two distinct entities. <i>Diabetes/Metabolism Research and Reviews</i> , 2022, 38, e3535.	4.0	4
146	Endobronchial Carcinoid Tumor Totally Occluding the Left Main Bronchus Without Producing Symptoms of Bronchial Obstruction. <i>In Vivo</i> , 2018, 31, 1023-1025.	1.3	3
147	Combined Use of Mammography and FNA Eliminates Pitfalls in the Management of Metaplastic Breast Carcinoma. <i>In Vivo</i> , 2017, 31, 737-740.	1.3	2
148	Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 23-28.	0.4	2
149	Screening for Gaucher disease among patients with plasma cell dyscrasias. <i>Leukemia and Lymphoma</i> , 2021, 62, 761-763.	1.3	2
150	Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World "POWERFUL" Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1509.	2.4	2
151	Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study). <i>Blood</i> , 2019, 134, 1837-1837.	1.4	2
152	Clinical biomarkers directing the management of patients with colon and lung cancer (beyond) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 46</i>	0.2	2
153	Newly Diagnosed Multiple Myeloma Patients with Skeletal-Related Events and Abnormal MRI Pattern Have Poor Survival Outcomes: A Prospective Study on 370 Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 3088.	2.4	2
154	Real World Treatment of Patients with Relapsed/Refractory Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S24-S27.	0.4	1
155	Activin-A is elevated in patients with thalassemia major and double heterozygous sickle cell/beta-thalassemia and correlates with markers of hemolysis and bone mineral density. <i>Annals of Hematology</i> , 2019, 98, 1583-1592.	1.8	1
156	Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction. <i>Journal of Clinical Medicine</i> , 2020, 9, 3201.	2.4	1
157	A Molecular Signature of Three tRNA-Derived RNA Fragments May Discriminate Smoldering from Symptomatic Multiple Myeloma Patients. <i>Blood</i> , 2019, 134, 5528-5528.	1.4	1
158	Successful treatment with lenalidomide dexamethasone for second relapse of a patient with non-secretory multiple myeloma with extramedullary liver plasmacytomas: A case report. <i>Hematology &amp; Medical Oncology</i> , 2017, 2, .	0.1	1
159	Second Primary Malignancies and Disease Transformation in Newly Diagnosed Symptomatic Patients with Waldenstrom's Macroglobulinemia: An Analysis from the Greek Myeloma Study Group. <i>Blood</i> , 2018, 132, 1978-1978.	1.4	1
160	Functional Cure, Defined As PFS of More Than 7 Years, Is Achieved in 9% of Myeloma Patients in the Era of Conventional Chemotherapy and of First-Generation Novel Anti-Myeloma Agents; A Single-Center Experience over 20-Year Period. <i>Blood</i> , 2018, 132, 1968-1968.	1.4	1
161	Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) As a Biomarker of Renal Outcomes in AL Amyloidosis. <i>Blood</i> , 2020, 136, 33-33.	1.4	1
162	Current trends in the management and prevention of human papillomavirus (HPV) infection. <i>Jbuon</i> , 2020, 25, 1281-1285.	0.3	1

#	ARTICLE	IF	CITATIONS
163	Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma who Are Treated with Bortezomib-Based Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S325.	0.4	0
164	Primary Treatment of Light Chain (AL) Amyloidosis with Bortezomib, Lenalidomide and Dexamethasone (VRD). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S331-S332.	0.4	0
165	Primary plasma cell leukemia presenting as secondary pulmonary alveolar proteinosis. <i>Leukemia and Lymphoma</i> , 2020, 61, 2246-2249.	1.3	0
166	Therapy of Myeloma Bone Disease. , 2021, , 111-137.		0
167	Recent therapeutic approaches in myeloma. , 2022, , 1019-1029.		0
168	Primary Treatment of Light Chain (AL) Amyloidosis with Bortezomib, Lenalidomide and Dexamethasone (VRD). <i>Blood</i> , 2018, 132, 3248-3248.	1.4	0
169	Serum Neutrophil Gelatinase-Associated Lipocalin Independently Predicts for Renal Response in Myeloma Patients with Severe Renal Impairment. <i>Blood</i> , 2019, 134, 1877-1877.	1.4	0
170	Pulmonary Function Tests Reveal Unrecognized Lung Dysfunction and Have Independent Prognostic Significance in Patients with Systemic AL Amyloidosis. <i>Blood</i> , 2019, 134, 1842-1842.	1.4	0
171	Kinetics of Anti-Sars-Cov-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. <i>Blood</i> , 2021, 138, 4202-4202.	1.4	0
172	IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure. <i>Blood</i> , 2020, 136, 12-12.	1.4	0
173	A Prospective Study and Identification of Genomewide Association Markers of Familial Predisposition to Plasma Cell Dyscrasias. <i>Blood</i> , 2020, 136, 8-8.	1.4	0
174	Efficacy of Daratumumab Monotherapy on Bone Metabolism of Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results from the Phase 2 Rebuild Study. <i>Blood</i> , 2020, 136, 29-29.	1.4	0
175	The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma. <i>Blood</i> , 2020, 136, 6-7.	1.4	0
176	Challenging management of synchronous cancers presenting with dysphagia. <i>Journal of B U on</i> , 2017, 22, 280-281.	0.4	0
177	Multidisciplinary management of complicated small bowel adenocarcinoma on the ground of Crohn's disease. <i>Jbuon</i> , 2019, 24, 408-409.	0.3	0
178	Clear cell sugar tumor of the lung; a systematic review for a rare entity. <i>Jbuon</i> , 2021, 26, 17-32.	0.3	0